Multiple treatment strategies have been evaluated for COVID-19, including chloroquine and hydroxychloroquine (membrane fusion and endocytosis inhibitors), arbidol (viral envelope membrane fusion inhibitor), remdesivir, ribavirin, and favipiravir (viral RNA-dependent RNA polymerase inhibitors), lopinavir and darunavir (chymotrypsin-like protease inhibitors), and tocilizumab and sarilumab (interleukin-6 [IL-6] inhibitors) (10). Here, IL6 is linked to COVID-19.